Objective: To study the clinical effect of pramipexole hydrochloride combined with benserazide hydrochloride on Parkinson disease.Methods: 160 cases of patients with Parkinson disease treated in the hospital from January 2012 to December 2016 were randomly divided into observation group and control group (n=80). The control group was treated with benserazide hydrochloride. The observation group was treated with pramipexole hydrochloride combined with benserazide hydrochloride. The motor function, the UPDRS score before and after treatment, and the incidence of adverse reactions such as nausea, vomiting, switching, psychiatric symptoms and so on were compared between the two groups.Results: The effective rate in the observation group was 95.00 %, which was significantly higher than that in the control group (83.75 %) (P＜0.05). The UPDRS scores of the two groups significantly decreased (P＜0.05) and the scores in the observation group was significantly lower than those in the control group (P＜0.05). There was no significant difference in the incidence of adverse reactions such as nausea, vomiting, switching phenomenon and psychiatric symptoms in the two groups (P＞0.05).Conclusion: Pramipexole hydrochloride combined with benserazide hydrochloride is safe and effective in the treatment of Parkinson disease, which can significantly improve the motor function of patients. It is worthy of promotion.